The Compensation Committee of INOVIO’s Board of Directors has approved the award of restricted stock units (“RSU”s) covering an aggregate of 9,307 shares of common stock and an option to purchase an aggregate of 12,100 shares of common stock, with a grant date of July 31, 2024 (the “Grant Date”), to a newly hired employee in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over a three-year period, with one-third of the shares vesting on each of the first, second and third anniversaries of the Grant Date. The stock option has an exercise price of
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO’s technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media:
Investors:
https://i-invdn-com.investing.com/news/World_News_9_800x533_L_1420026261.jpg
Source link
Investing.com